[ad_1]
Original title: “Medicines that save lives” “fly” into the homes of ordinary people at low prices
Yesterday, the National Administration of Health Insurance, Human Resources andsocietyThe Ministry of Security announced the “National Basic Medicalinsurance、Work injuryinsuranceAnd fertilityinsuranceDrug Catalog (2020) “, this round of national health insurancenegotiationThe incorporation of multiple antitumor drugs in the national health insurance catalog demonstrates the country’s care for cancer patients. “Life-saving drugs” can be extremely lowprice“Fly to” the homes of ordinary people.
According to nationalpopularAccording to medical data, lung cancer, liver cancer, and esophageal cancer ranked first, third and fifth in the number of new cancer patients in China. Improve the survival rate and cure rate of the Cancer patients has always been important to the development of China’s medical industry.objectives. In recent years, the development of tumor immunotherapy has played a key role in this. The PD-1 / PD-L1 antibody drug is considered the greatest advance in this field in recent years. Used alone or in combination with other drugs, it can be widely applied to a variety of cancer patients.But at the same time, the development of such drugscostExtremely high,Salesexpensive.In the early years, our country only had foreign countriesto importThe PD-1 antibody drug is on the market, and its annual treatment cost of hundreds of thousands of dollars has put off many families.
The enthusiasm of the patientdemandAnd the high cost is a big problem for patients How to make “magic medicine” for disease treatment become “good medicine” that patients can afford is also a national policy and China’s innovative medicine in the last years.companyProblems to be solved. In the past two years, research and development of domestically produced PD-1 antibody drugs have overcome this dilemma. In this year’s health insurance negotiations, access to PD-1 inhibitors has become the biggest focus due to the drugs involved in many different cancer patients. And the result is that many cancer patients and their families they wanted the domestically made PD-1 inhibitor with the most approved indications in China.Hengrui MedicineThe Karelizumab produced successfully entered the medical insurance catalog and became the only medical insurance in the fields of lung cancer, liver cancer and esophageal cancer.RefundOf immunotherapy drugs.
In the clinical diagnosis and treatment guidelines for lung cancer, liver cancer, esophageal cancer and lymphoma published by the Chinese Society of Clinical Oncology (CSCO) in 2020, carrelizumab has been included in the guideline recommendation and has been become the only immunotherapy drug in China to have achieved this achievement. .
On December 19, the authoritative international medical journal “The Lancet-Respiratory Medicine” published the full text online of Karelizumab against advanced non-squamous non-small cell lung cancer.Combination therapyPhase III Clinical Trial Investigation Results The lead investigator of the clinical trial, Zhou Caicun, Director of the Institute of Oncology at Tongji University School of Medicine and Director of the Department of Oncology at Shanghai Pulmonary Hospital.professorHe said: “From current research data, the efficacy of domestically produced PD-1, such as carrelizumab, is not inferior to similar imported drugs, but there are also many highlights. Now the country has included PD-1 high-quality national production in health insurance “. “It is a great help for cancer patients. We are very confident in completing the tasks assigned to us by the government and increasing the five-year cancer survival rate to 43.3%.”
In recent years, China has benefited from a number of favorable policies, such as the standardization of the medical insurance catalog. More and more high-quality national innovative drugs and “life-saving drugs” are “flying” into the homes of ordinary people at ultra-low prices. In the future, with the rapid development of China’s medical scientific research, China’s independently developed and produced anticancer drugs will benefit more people and bring hope of survival to more cancer patients.
(Source: China Net Finance)
(Responsible editor: DF537)
I solemnly declare: The purpose of this information disclosed by Oriental Fortune.com is to spread more information and has nothing to do with this booth.
[ad_2]